Items Tagged ‘Alecensa’

April 24, 2018

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer

By

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of […]

View full entry

Tags: Alcensa, Alecensa, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, non-small cell lung cancer, xalkori


September 21, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine